Posterior pelvic exenteration, a crucial component in the surgeon's toolbox for optimizing surgical cytoreduction for advanced ovarian cancer.
作者信息
Moukarzel Lea A, Chi Dennis S
机构信息
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
J Gynecol Oncol. 2022 May;33(3):e41. doi: 10.3802/jgo.2022.33.e41. Epub 2022 Feb 21.
Abstract
摘要
相似文献
1
Posterior pelvic exenteration, a crucial component in the surgeon's toolbox for optimizing surgical cytoreduction for advanced ovarian cancer.后盆腔脏器清除术是外科医生用于优化晚期卵巢癌手术细胞减灭术的重要手段。
J Gynecol Oncol. 2022 May;33(3):e41. doi: 10.3802/jgo.2022.33.e41. Epub 2022 Feb 21.
2
Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.肠系膜淋巴结受累在晚期卵巢癌根治性或超根治性手术中行后盆腔脏器清除术患者中的预后作用
Arch Gynecol Obstet. 2018 Apr;297(4):997-1004. doi: 10.1007/s00404-018-4675-y. Epub 2018 Jan 27.
3
Ghost ileostomy in advanced ovarian cancer.
Gynecol Oncol. 2017 Nov;147(2):488. doi: 10.1016/j.ygyno.2017.08.017. Epub 2017 Aug 31.
4
Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.卵巢癌的盆腔后切除术：手术和肿瘤学结果。
J Gynecol Oncol. 2022 May;33(3):e31. doi: 10.3802/jgo.2022.33.e31. Epub 2022 Feb 4.
5
Step-by-step total pelviperitonectomy with modified posterior pelvic exenteration.
Int J Gynecol Cancer. 2020 Apr;30(4):558. doi: 10.1136/ijgc-2019-000984. Epub 2020 Jan 6.
6
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.新辅助化疗后延迟细胞减灭术治疗晚期上皮性卵巢癌的生存结局。
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942. doi: 10.1136/ijgc-2020-001658. Epub 2020 Oct 29.
7
[Postoperative morbidities after modified posterior pelvic exenteration for ovarian cancer].[卵巢癌改良后盆腔脏器清除术后的术后并发症]
Gynecol Obstet Fertil. 2015 May;43(5):342-7. doi: 10.1016/j.gyobfe.2015.03.006. Epub 2015 Apr 18.
8
[Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].[Ⅲc期上皮性卵巢癌“卷地毯式”肿瘤细胞减灭术的技术要点与安全性分析]
Zhonghua Fu Chan Ke Za Zhi. 2020 Aug 25;55(8):521-528. doi: 10.3760/cma.j.cn112141-20200313-00218.
9
Primary Cytoreduction and Survival for Patients With Less-Common Epithelial Ovarian Cancer.少见上皮性卵巢癌患者的初次肿瘤细胞减灭术与生存情况
JAMA Netw Open. 2024 Jun 3;7(6):e2417775. doi: 10.1001/jamanetworkopen.2024.17775.
10
Modified posterior pelvic exenteration for advanced ovarian malignancies: a single-institution study of 35 cases.
Acta Obstet Gynecol Scand. 2017 Sep;96(9):1136-1143. doi: 10.1111/aogs.13177. Epub 2017 Jul 6.
引用本文的文献
1
Prognostic Factors and a Predictive Nomogram of Cancer-Specific Survival of Epithelial Ovarian Cancer Patients with Pelvic Exenteration Treatment.盆腔廓清术治疗上皮性卵巢癌患者的预后因素和癌症特异性生存预测列线图。
Int J Clin Pract. 2023 Aug 17;2023:9219067. doi: 10.1155/2023/9219067. eCollection 2023.
本文引用的文献
1
Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.卵巢癌的盆腔后切除术：手术和肿瘤学结果。
J Gynecol Oncol. 2022 May;33(3):e31. doi: 10.3802/jgo.2022.33.e31. Epub 2022 Feb 4.
2
Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?在晚期卵巢癌的初级减瘤术中不断改进：更高的完全大体切除率是否能独立提高无进展生存期和总生存期？
Gynecol Oncol. 2018 Oct;151(1):24-31. doi: 10.1016/j.ygyno.2018.08.014. Epub 2018 Aug 17.
3
Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.腹腔镜手术算法在晚期卵巢癌中对肿瘤减瘤手术时机进行分类。
Obstet Gynecol. 2018 Sep;132(3):545-554. doi: 10.1097/AOG.0000000000002796.
4
A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.一项关于术前计算机断层扫描和CA-125预测晚期上皮性卵巢癌初次肿瘤细胞减灭术时肉眼残留病灶能力的多中心评估。
Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14.
5
Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.最大限度地减灭肿瘤细胞可改善卵巢癌患者的生存，即使完全肉眼可见的肿瘤切除无法实现。
Gynecol Oncol. 2017 Apr;145(1):21-26. doi: 10.1016/j.ygyno.2017.01.029. Epub 2017 Jan 31.
6
Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes.卵巢癌初次肿瘤细胞减灭术中的转流性回肠造口术：相关因素及术后结局
Gynecol Oncol. 2016 Aug;142(2):217-24. doi: 10.1016/j.ygyno.2016.05.035. Epub 2016 Jun 4.
7
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.新诊断的晚期卵巢癌的初次化疗与初次手术（CHORUS）：一项开放标签、随机、对照、非劣效性试验。
Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19.
8
Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy.接受初次肿瘤细胞减灭术与新辅助化疗治疗的高肿瘤播散的卵巢癌患者的复发时间和模式。
Ann Surg Oncol. 2013 Nov;20(12):3955-60. doi: 10.1245/s10434-013-3091-6. Epub 2013 Jul 10.
9
Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes.直肠乙状结肠切除术在原发性细胞减灭术治疗晚期卵巢癌中的应用。一项多中心手术和肿瘤学结局分析。
Gynecol Oncol. 2012 Aug;126(2):220-3. doi: 10.1016/j.ygyno.2012.04.030. Epub 2012 Apr 30.
10
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.新辅助化疗与初始肿瘤细胞减灭术用于 IIIC 或 IV 期卵巢癌。
N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.
Zotero 插件